The favourable alliance between CardioMEMS and levosimendan in patients with advanced heart failure.
CardioMEMS
Heart failure
Levosimendan
Telemonitoring
Journal
ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191
Informations de publication
Date de publication:
18 May 2024
18 May 2024
Historique:
revised:
07
04
2024
received:
12
01
2024
accepted:
17
04
2024
medline:
18
5
2024
pubmed:
18
5
2024
entrez:
18
5
2024
Statut:
aheadofprint
Résumé
We report the results of a real-world study based on heart failure (HF) patients' continuous remote monitoring strategy using the CardioMEMS system to assess the impact of this device on healthcare outcomes, costs, and patients' management and quality of life. We enrolled seven patients (69.00 ± 4.88 years; 71.43% men) with HF, implanted with CardioMEMS, and daily remote monitored to optimize both tailored adjustments of home therapy and/or hospital infusions of levosimendan. We recorded clinical, pharmacological, biochemical, and echocardiographic parameters and data on hospitalizations, emergency room access, visits, and costs. Following the implantation of CardioMEMS, we observed a 50% reduction in the total number of hospitalizations and a 68.7% reduction in the number of days in the hospital. Accordingly, improved patient quality of life was recorded with EQ-5D (pre 58.57 ± 10.29 vs. 1 year post 84.29 ± 19.02, P = 0.008). Echocardiographic data show a statistically significant improvement in both systolic pulmonary artery pressure (47.86 ± 8.67 vs. 35.14 ± 9.34, P = 0.022) and E/e' (19.33 ± 5.04 vs. 12.58 ± 3.53, P = 0.023). The Quantikine® HS High-Sensitivity Kit determined elevated interleukin-6 values at enrolment in all patients, with a statistically significant reduction after 6 months (P = 0.0211). From an economic point of view, the net savings, including the cost of CardioMEMS, were on average €1580 per patient during the entire period of observation, while the analysis performed 12 months after the implant vs. 12 months before showed a net saving of €860 per patient. The ad hoc analysis performed on the levosimendan infusions resulted in 315 days of hospital avoidance and a saving of €205 158 for the seven patients enrolled during the observation period. This innovative strategy prevents unplanned access to the hospital and contributes to the efficient use of healthcare facilities, human resources, and costs.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : SOLOMAX SociaLNetwOrk of MedicAlEXperiences
ID : F/260007/05/X51-CUP: B49J21031700008
Organisme : Innovation Agreement D.M. 02.8.2019 Life Sciences-MISE
Informations de copyright
© 2024 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
Authors/Task Force Members, McDonagh T, Metra M, Adamo M, Gardner RS, Baumbach A, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2022;24:4‐131. doi:10.1002/ejhf.2333
Visco V, Esposito C, Manzo M, Fiorentino A, Galasso G, Vecchione C, et al. A multistep approach to deal with advanced heart failure: A case report on the positive effect of cardiac contractility modulation therapy on pulmonary pressure measured by CardioMEMS. Front Cardiovasc Med 2022;9:874433. doi:10.3389/fcvm.2022.874433
Butler J, Yang M, Manzi MA, Hess GP, Patel MJ, Rhodes T, et al. Clinical course of patients with worsening heart failure with reduced ejection fraction. J Am Coll Cardiol 2019;73:935‐944. doi:10.1016/j.jacc.2018.11.049
Ciccarelli M, Giallauria F, Carrizzo A, Visco V, Silverio A, Cesaro A, et al. Artificial intelligence in cardiovascular prevention: New ways will open new doors. J Cardiovasc Med (Hagerstown) 2023;24:e106‐e115. doi:10.2459/JCM.0000000000001431
Martinson M, Bharmi R, Dalal N, Abraham WT, Adamson PB. Pulmonary artery pressure‐guided heart failure management: US cost‐effectiveness analyses using the results of the CHAMPION clinical trial. Eur J Heart Fail 2017;19:652‐660. doi:10.1002/ejhf.642
Guha K, McDonagh T. Heart failure epidemiology: European perspective. Curr Cardiol Rev 2013;9:123‐127. doi:10.2174/1573403x11309020005
Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, et al. Forecasting the impact of heart failure in the United States: A policy statement from the American Heart Association. Circ Heart Fail 2013;6:606‐619. doi:10.1161/HHF.0b013e318291329a
Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: A comprehensive and updated review of epidemiology. Cardiovasc Res 2023;118:3272‐3287. doi:10.1093/cvr/cvac013
Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee‐for‐service program. N Engl J Med 2009;360:1418‐1428. doi:10.1056/NEJMsa0803563
Ayyadurai P, Alkhawam H, Saad M, al‐Sadawi MA, Shah NN, Kosmas CE, et al. An update on the CardioMEMS pulmonary artery pressure sensor. Ther Adv Cardiovasc Dis 2019;13:1753944719826826. doi:10.1177/1753944719826826
Cook C, Cole G, Asaria P, Jabbour R, Francis DP. The annual global economic burden of heart failure. Int J Cardiol 2014;171:368‐376. doi:10.1016/j.ijcard.2013.12.028
Maggioni AP, Orso F, Calabria S, Rossi E, Cinconze E, Baldasseroni S, et al. The real‐world evidence of heart failure: Findings from 41 413 patients of the ARNO database. Eur J Heart Fail 2016;18:402‐410. doi:10.1002/ejhf.471
Visco V, Radano I, Campanile A, Ravera A, Silverio A, Masarone D, et al. Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF. ESC Heart Fail 2022;9:2909‐2917. doi:10.1002/ehf2.13982
Campanile A, Visco V, de Carlo S, Ferruzzi GJ, Mancusi C, Izzo C, et al. Sacubitril/valsartan vs. standard medical therapy on exercise capacity in HFrEF patients. Life (Basel) 2023;13:1174. doi:10.3390/life13051174
McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin‐neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993‐1004. doi:10.1056/NEJMoa1409077
Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005;352:1539‐1549. doi:10.1056/NEJMoa050496
Ong MK, Romano PS, Edgington S, Aronow HU, Auerbach AD, Black JT, et al. Effectiveness of remote patient monitoring after discharge of hospitalized patients with heart failure: The Better Effectiveness After Transition—Heart Failure (BEAT‐HF) randomized clinical trial. JAMA Intern Med 2016;176:310‐318. doi:10.1001/jamainternmed.2015.7712
Visco V, Ferruzzi GJ, Nicastro F, Virtuoso N, Carrizzo A, Galasso G, et al. Artificial intelligence as a business partner in cardiovascular precision medicine: An emerging approach for disease detection and treatment optimization. Curr Med Chem 2021;28:6569‐6590. doi:10.2174/0929867328666201218122633
Klein L. (Re)discovering the neurohormonal and hemodynamic duality of heart failure. J Am Coll Cardiol 2017;70:1887‐1889. doi:10.1016/j.jacc.2017.08.058
Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: A randomised controlled trial. Lancet 2011;377:658‐666. doi:10.1016/S0140‐6736(11)60101‐3
Schmier JK, Ong KL, Fonarow GC. Cost‐effectiveness of remote cardiac monitoring with the CardioMEMS heart failure system. Clin Cardiol 2017;40:430‐436. doi:10.1002/clc.22696
Brugts JJ, Veenis JF, Radhoe SP, Linssen GCM, van Gent M, Borleffs CJW, et al. A randomised comparison of the effect of haemodynamic monitoring with CardioMEMS in addition to standard care on quality of life and hospitalisations in patients with chronic heart failure: Design and rationale of the MONITOR HF multicentre randomised clinical trial. Neth Heart J 2020;28:16‐26. doi:10.1007/s12471‐019‐01341‐9
Savoia E, Fantini MP, Pandolfi PP, Dallolio L, Collina N. Assessing the construct validity of the Italian version of the EQ‐5D: Preliminary results from a cross‐sectional study in North Italy. Health Qual Life Outcomes 2006;4:47. doi:10.1186/1477‐7525‐4‐47
Pocock SJ, Ariti CA, McMurray JJ, Maggioni A, Køber L, Squire IB, et al. Predicting survival in heart failure: A risk score based on 39 372 patients from 30 studies. Eur Heart J 2013;34:1404‐1413. doi:10.1093/eurheartj/ehs337
Lang RM, Badano LP, Mor‐Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2015;16:233‐270. doi:10.1093/ehjci/jev014
Comín‐Colet J, Manito N, Segovia‐Cubero J, Delgado J, García Pinilla JM, Almenar L, et al. Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: The LION‐HEART multicentre randomised trial. Eur J Heart Fail 2018;20:1128‐1136. doi:10.1002/ejhf.1145
Ortis B, Villani A, Oldani M, Giglio A, Ciambellotti F, Facchini M, et al. Intermittent levosimendan infusions in advanced heart failure: A real world experience. J Int Med Res 2017;45:361‐371. doi:10.1177/0300060516655244
Cowie MR, Flett A, Cowburn P, Foley P, Chandrasekaran B, Loke I, et al. Real‐world evidence in a national health service: Results of the UK CardioMEMS HF System Post‐Market Study. ESC Heart Fail 2022;9:48‐56. doi:10.1002/ehf2.13748
Angermann CE, Assmus B, Anker SD, Asselbergs FW, Brachmann J, Brett ME, et al. Pulmonary artery pressure‐guided therapy in ambulatory patients with symptomatic heart failure: The CardioMEMS European Monitoring Study for Heart Failure (MEMS‐HF). Eur J Heart Fail 2020;22:1891‐1901. doi:10.1002/ejhf.1943
Vaduganathan M, DeFilippis EM, Fonarow GC, Butler J, Mehra MR. Postmarketing adverse events related to the CardioMEMS HF system. JAMA Cardiol 2017;2:1277‐1279. doi:10.1001/jamacardio.2017.3791
Shirazi LF, Bissett J, Romeo F, Mehta JL. Role of inflammation in heart failure. Curr Atheroscler Rep 2017;19:27. doi:10.1007/s11883‐017‐0660‐3
Tamariz L, Hare JM. Inflammatory cytokines in heart failure: Roles in aetiology and utility as biomarkers. Eur Heart J 2010;31:768‐770. doi:10.1093/eurheartj/ehq014
Markousis‐Mavrogenis G, Tromp J, Ouwerkerk W, Devalaraja M, Anker SD, Cleland JG, et al. The clinical significance of interleukin‐6 in heart failure: Results from the BIOSTAT‐CHF study. Eur J Heart Fail 2019;21:965‐973. doi:10.1002/ejhf.1482
Ridker PM, Rane M. Interleukin‐6 signaling and anti‐interleukin‐6 therapeutics in cardiovascular disease. Circ Res 2021;128:1728‐1746. doi:10.1161/CIRCRESAHA.121.319077
Visco V, Esposito C, Vitillo P, Vecchione C, Ciccarelli M. It is easy to see, but it is better to foresee: A case report on the favourable alliance between CardioMEMS and levosimendan. Eur Heart J Case Rep 2020;4:1‐5. doi:10.1093/ehjcr/ytaa205
Shahar E, Lee S, Kim J, Duval S, Barber C, Luepker RV. Hospitalized heart failure: Rates and long‐term mortality. J Card Fail 2004;10:374‐379. doi:10.1016/j.cardfail.2004.02.003
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 2017;136:e137‐e161. doi:10.1161/CIR.0000000000000509
Brugts JJ, Radhoe SP, Clephas PRD, Aydin D, van Gent MWF, Szymanski MK, et al. Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR‐HF): A randomised clinical trial. Lancet 2023;401:2113‐2123. doi:10.1016/S0140‐6736(23)00923‐6
Desai AS, Bhimaraj A, Bharmi R, Jermyn R, Bhatt K, Shavelle D, et al. Ambulatory hemodynamic monitoring reduces heart failure hospitalizations in “real‐world” clinical practice. J Am Coll Cardiol 2017;69:2357‐2365. doi:10.1016/j.jacc.2017.03.009
Sandhu AT, Goldhaber‐Fiebert JD, Owens DK, Turakhia MP, Kaiser DW, Heidenreich PA. Cost‐effectiveness of implantable pulmonary artery pressure monitoring in chronic heart failure. JACC Heart Fail 2016;4:368‐375. doi:10.1016/j.jchf.2015.12.015
Zile MR, Desai AS, Costanzo MR, Ducharme A, Maisel A, Mehra MR, et al. The GUIDE‐HF trial of pulmonary artery pressure monitoring in heart failure: Impact of the COVID‐19 pandemic. Eur Heart J 2022;43:2603‐2618. doi:10.1093/eurheartj/ehac114